Form 4: Inozyme Pharma SVP, CFO Sanjay Subramanian Reports Stock Option Grant

Sanjay Subramanian, SVP and CFO of Inozyme Pharma, reports the acquisition of stock options.

Summary

• On March 13, 2024, Sanjay Subramanian, the SVP and CFO of Inozyme Pharma, Inc. (INZY), reported a transaction.
• Subramanian acquired 165,000 stock options with an exercise price of $5.77.
• The options were granted on March 13, 2024, and vest in equal monthly installments until the fourth anniversary of the grant date.
• Following the transaction, Subramanian directly owns 165,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grant of options is generally a positive sign, aligning executive interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a key executive like the CFO can be seen as an incentive to align their interests with the long-term success of the company.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech/pharmaceutical industry.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of the shareholders, incentivizing him to increase shareholder value.

Key Dates